U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 431 - 440 of 13362 results

Status:
Possibly Marketed Outside US
Source:
XT-1 Pre-Post Part A by AgroChem USA, LLC
(2022)
Source URL:
First approved in 2021

Class (Stereo):
CHEMICAL (RACEMIC)

Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)

Conditions:

Cedryl acetate is widely used as the aroma in daily chemicals (content less than 20%). It also can be used in food approved by FDA but not more than 1m/kg. It was shown, that cedryl acetate possesses α-glucosidase inhibitory activity.
Status:
Possibly Marketed Outside US
Source:
Hepad S5 by YOUNGJIN Korean Medicine Clinic
(2021)
Source URL:
First approved in 2021
Source:
Hepad S5 by YOUNGJIN Korean Medicine Clinic
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Corynoxeine is a compound isolated from Uncaria rhynchophylla, a traditional Chinese herb that has been applied to the treatment of convulsive disorders in China. Corynoxeine was found to inhibit PDGF-BB-induced activation of ERK1/2 and vascular smooth muscle cells proliferation. Corynoxeine found to induce autophagy in different neuronal cell lines, including N2a and SHSY-5Y cells and may have potential application for the prevention or treatment of Parkinson's disease.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)

Targets:


Verdinexor (KPT-335) is a small-molecule selective inhibitor of nuclear export (SINE). Karyopharm Therapeutics has recently developed first-in-class, novel SINE compounds using molecular modeling to screen a small virtual library of compounds against the NES groove of human exportin-1 (XPO1). These compounds inhibit nuclear-cytoplasmic export by reversibly binding to the cargo recognition site of XPO1 and are orally bioavailable. Verdinexor was shown to potently and selectively inhibit vRNP export and effectively inhibited the replication of various influenza virus A and B strains in vitro, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain. Verdinexor is in development for the treatment of viral indications. Verdinexor is being evaluated for the treatment of lymphomas in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Possibly Marketed Outside US
Source:
Hepad S5 by YOUNGJIN Korean Medicine Clinic
(2021)
Source URL:
First approved in 2021
Source:
Hepad S5 by YOUNGJIN Korean Medicine Clinic
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Proximadiol was isolated from the rhizomes of Zingiber mekongense and leaves of Blumea balsamifera. Compound lacks ativiral and antibacterial activity. Proximadiol was found to inhibit platelet-activating factor receptor binding on platelets at micromolar concentrations.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)


There is no information related to the biological or pharmacological application of Sodium ferrocyanide decahydrate. It is known, that this substance is used for bleaching, toning, and fixing in photography, and in the petroleum industry, as a removal of mercaptans.